Print Page  Close Window

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$7.18
Change (%) Stock is Up 0.33 (4.82%)
Volume492,917
Data as of 11/14/18 4:00 p.m. ET

Latest News

11/06/18
Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results
11/01/18
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
10/26/18
Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018
10/04/18
Paratek Announces Acceptance of European Marketing Authorization Application for Oral and Intravenous Omadacycline
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.